Epoetin Alfa (Epogen)

A recombinant glycosylated form of erythropoietin which stimulates the differentiation and proliferation of erythroid precursors. It is used for the treatment of ANEMIA associated with CHRONIC RENAL FAILURE in dialysis and predialysis patients.

Also Known As:

Epogen; Binocrit; Epoetin Alfa Hexal; Eprex; HX575; HX575 Compound; Heberitro; Procrit; Recombinant 1-165 Erythropoietin, Glycoform Alpha; Alfa Hexal, Epoetin; Alfa, Epoetin; Compound, HX575; Hexal, Epoetin Alfa; Recombinant 1 165 Erythropoietin, Glycoform Alpha; 1-165-Erythropoietin (human clone lambdaHEPOFL13 protein moiety), glycoform alpha

Networked: 677 relevant articles (134 outcomes, 225 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Lefebvre, Patrick: 14 articles (01/2012 - 11/2005)
2.	Henry, David H: 11 articles (02/2007 - 01/2004)
3.	Casadevall, Nicole: 10 articles (10/2017 - 05/2004)
4.	Duh, Mei Sheng: 10 articles (07/2008 - 08/2005)
5.	Williams, Denise: 10 articles (12/2007 - 06/2005)
6.	Fishbane, Steven: 9 articles (01/2022 - 07/2005)
7.	Mody, Samir H: 9 articles (09/2007 - 12/2004)
8.	Piech, Catherine Tak: 8 articles (05/2008 - 09/2005)
9.	McKenzie, R Scott: 8 articles (09/2007 - 09/2005)
10.	Singh, Ajay K: 7 articles (01/2022 - 11/2006)

Related Diseases

1.	Anemia 08/01/2003 - "Epoetin alfa has proven efficacy and safety in correcting anemia and improving QOL based on numerous clinical studies and over a decade of clinical practice. " 02/01/2006 - "Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl." 01/01/2018 - "In addition to the comparability exercises, extensive clinical experience over the last decade also confirms that HX575 provides an effective treatment for CKD-related anemia, with a favorable safety profile. " 10/01/2017 - "SC HX575 was effective for correcting and maintaining correction of anemia, and the mean weekly dose remained stable over time. ." 12/01/2002 - "Anemia occurs early in CKD and can be effectively treated with epoetin alfa. "
2.	Neoplasms (Cancer) 01/01/2005 - "This confirmed that QoL is correlated with haemoglobin levels and that treatment with epoetin alfa is associated with a significant improvement in QoL as measured by validated cancer-specific instruments such as FACT and CLAS. " 12/01/2009 - "Postoperative epoetin alfa (40,000 units subcutaneous on postoperative days 1 and 7) is associated with improved hematologic parameters in patients undergoing major abdominal surgery for malignancy. " 01/01/2004 - "These findings support the use of epoetin alfa to achieve gains in QOL and cancer treatment outcomes in anemic cancer patients and suggest that additional studies be conducted to further investigate the potential benefits of this agent in regard to improved outcomes." 01/01/2005 - "Treatment with epoetin alfa has repeatedly been shown to improve the quality of life (QoL) of cancer patients with anaemia. " 09/01/2001 - "Improvement in quality of life for cancer patients treated with epoetin alfa."
3.	Chronic Kidney Failure (Chronic Renal Failure) 04/01/1998 - "Since this program's inception, advances in technology (e.g., better dialysis equipment) and pharmacology (e.g., maintenance of an optimum hematocrit with Epoetin alfa) have greatly improved the care of patients with ESRD and increased the potential for successful rehabilitation. " 01/03/2022 - "Correction to: A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in patients with anaemia of chronic renal failure." 01/01/2004 - "Anaemia correction in patients with end-stage renal disease has been enhanced following the use of epoetin alfa or beta and there are a number of studies detailing its application. " 01/01/2004 - "A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta." 08/01/1989 - "Clinical studies have demonstrated that Epoetin alfa effectively maintains RBC levels, decreases the need for transfusions, and improves the overall quality of life in anemic, ESRD, dialysis patients. "
4.	Chronic Renal Insufficiency 01/01/2005 - "Eprex was administered intravenously to chronic kidney disease patients and, with improved storage and handling, there was a subsequent dramatic reduction in the number of cases. " 07/01/2008 - "Emerging evidence suggests that epoetin alfa can be administered at extended intervals of up to 4 wk. This open-label, randomized study was performed to characterize the pharmacokinetic and pharmacodynamic profiles of four dosing regimens of epoetin alfa administered subcutaneously in anemic patients who had chronic kidney disease and were not on dialysis. " 05/01/2007 - "The study patients had chronic kidney disease but were not receiving dialysis, had stable Hb levels of >or= 11.0 g/dL, and had been receiving epoetin alfa for >or= 2 months. " 08/01/2004 - "To evaluate the utility of a large-scale anti-EPO antibody screening program in patients with chronic kidney disease (CKD) administered epoetin alfa, a study involving 5 large renal centers in southern Ontario, Canada, was conducted. " 10/01/2017 - "To assess the safety and immunogenicity of subcutaneous (SC) HX575 (epoetin-α) in dialysis- and nondialysis-dependent adult patients with chronic kidney disease (CKD). "
5.	Breast Neoplasms (Breast Cancer) 07/01/2009 - "Leyland-Jones et al. conducted a study evaluating the effects of early intervention with epoetin alfa (40,000 units administered subcutaneously every week) on survival and QOL of mainly nonanemic patients with metastatic breast cancer. " 10/01/2004 - "The findings of the study demonstrate for the first time in patients with breast cancer that epoetin alfa significantly enhances functional well-being, which translates into significantly better utility scores. " 09/01/2004 - "Although the study was not designed or powered for survival as an endpoint, Kaplan-Meier estimates for the full cohort showed a trend in overall survival favoring epoetin alfa treatment (P = 0.13, log rank test); a similar benefit was seen in the breast cancer subpopulation. " 10/01/2003 - "It appears that epoetin alfa is a useful addition to the treatment of breast cancer." 01/01/2003 - "To determine the incremental cost utility of epoetin-alfa versus placebo in anaemic patients with stage IV breast cancer from a UK National Health Service perspective. "

Related Drugs and Biologics

1.	Hemoglobins (Hemoglobin)
2.	Erythropoietin
3.	Epoetin Alfa (Epogen)
4.	Darbepoetin alfa (Aranesp)
5.	Biosimilar Pharmaceuticals
6.	Platinum
7.	Hematinics
8.	Ribavirin (Virazole)
9.	Iron
10.	Intercellular Signaling Peptides and Proteins (Growth Factors)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Renal Dialysis (Hemodialysis)
4.	Blood Transfusion (Blood Transfusions)
5.	Erythrocyte Transfusion